PPT-Apixaban vs VKA and

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACSPCI The AUGUSTUS Trial Renato D Lopes MD PhD on behalf of the AUGUSTUS Investigators Background The optimal antithrombotic regimen for patients with atrial fibrillation AF who have an acute coronary syndrome ACS or require percutaneous coronary intervention PCI is unclear. G. . Turpie. Professor Emeritus of Medicine. McMaster University. Hamilton ON. Canada. Future Challenges. Disclosures for Dr A.G.G. Turpie. Research Support. None. Employee. None. Consultant and/or Honoraria. Active ingredient: apixaban.Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose Eliot Williams, MD PhD. Division of Hematology & Medical Oncology. History of anticoagulant therapy. 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010. st. century: A practical guide to using newer Agents. Katherine Vogel Anderson, . Pharm.D. ., BCACP. University of Florida Colleges of Pharmacy and Medicine. Disclosures . I have nothing to disclose. EVI. dence. on . S. troke prevention . I. n patients with . a. T. rial. Fibrillation in the . U. nited . S. tates . Craig I. . Coleman. , . Matthias . Antz. , . Edgar . Simard, . Thomas . Evers, . Kevin . tudes randomisées à la pratiq. ue. Dr D Coisne. d. s. /. d. t. >0. TTR: Time on . T. herapeutic. Range (2 to 3). Les AOD. AOD. FA . Etude randomisée, registres, . meta. -analyses, recommandations. A Look at New Oral Anticoagulants. Linda Wing, . R.Ph. .. Risik. Rask, . Pharm.D. .. Nothing to Disclose. Identify the characteristics of the ideal anticoagulant and the shortfalls with the current treatment options. Sponsored by Bristol-Myers Squibb and Pfizer. Samuel Z. Goldhaber, MD. Brigham and Women’s Hospital. Harvard Medical School. On behalf of the ADOPT Executive Committee. November 13, 2011. Disclosures. Anticoagulation and Thrombosis Management A Review of Non-Vitamin K Oral Anticoagulants: Other Uses Dabigatran Rivaroxaban Apixaban Edoxaban Target IIa (thrombin) Xa Xa Xa Hours to maximum concentration Christopher Granger, . MD. Sean Pokorney, MD. . Disclosure (Dr. Granger). Research contracts: AstraZeneca, Daiichi, Bayer, Novartis, GSK, Sanofi-Aventis, BMS, Pfizer, Medtronic Foundation, The Medicines Company, and Boehringer . Lanae Fox, . PharmD. , BCPS. I have no financial disclosures to report. Objectives. Understand the relative benefits and limitations of oral anticoagulant options. Recognize strategies for optimal use of oral anticoagulants and minimize risk of bleeding with these agents. �� Call your doctor or healthcare provider right away if you fall or injure yourself, especially if you hit your head. Your doctor or healthcare provider may need to check you. Wh S. urvivors for Stroke . P. revent. I. on. and . RE. covery. Mean reduction of 9/4 mm Hg. Of course you want to join the first ICH prevention study – . ASPIRE. – in recent NIH history! . This is a great trial to contribute to an active clinical practice question and a wonderful way to build out your StrokeNet trial portfolio!. Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP. Professor of Pharmacy Practice and Science. University of Nebraska Medical Center College of Pharmacy. Omaha, Nebraska USA. Disclosures. Consultant for the follow entities:.